On neuraminidase inhibitors and evidence-based medicine.
The quest initiated by the Cochrane authors to obtain the best available evidence on the efficacy of neuraminidase inhibitors is nearing completion, with complete divulging of individual patient data of the original randomized controlled trials. We will remain with the deficiencies of the original trials relating to the population studied, poor recording of clinically-significant complications and the data that were not kept. This experience should serve to improve the design of future trials, their documentation and preservation of patient data for future analyses.
Division of Infectious Diseases, Rambam Health Care Campus, Haifa, Israel. Electronic address: paulm@post.tau.ac.il.
M
M
Paul
Medicine E, Rabin Medical Center, Beilinson Hospital, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
L
L
Leibovici
D000998:Antiviral Agents / Q000494:pharmacology / Q000627:therapeutic use*; D004791:Enzyme Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D019317:Evidence-Based Medicine; D006801:Humans; D007251:Influenza, Human / Q000188:drug therapy*; D009439:Neuraminidase / Q000037:antagonists & inhibitors*
D000998:Antiviral Agents; D004791:Enzyme Inhibitors; D009439:Neuraminidase
Evidence; influenza; neuraminidase inhibitors; oseltamivir; zanamivir